Tuesday, July 1, 2025
News Health
  • Health News
  • Hair Products
  • Nutrition
    • Weight Loss
  • Sexual Health
  • Skin Care
  • Women’s Health
    • Men’s Health
No Result
View All Result
  • Health News
  • Hair Products
  • Nutrition
    • Weight Loss
  • Sexual Health
  • Skin Care
  • Women’s Health
    • Men’s Health
No Result
View All Result
HealthNews
No Result
View All Result
Home Health News

Nefecon Shows IgAN Benefits Regardless of Baseline eGFR

June 6, 2025
in Health News
Share on FacebookShare on Twitter


TOPLINE: 

Nefecon, an oral targeted-release formulation of budesonide that targets drug release into the distal ileum, provided significant improvements in the loss of kidney function in patients with immunoglobulin A nephropathy (IgAN) at 9 months, regardless of baseline estimated glomerular filtration rate (eGFR) status, according to a new subanalysis of the phase 3 NeflgArd study.

METHODOLOGY:

  • Patients in the NeflgArd study with primary IgAN were randomly assigned to one of two groups of 182 patients each to receive either treatment with 16 mg Nefecon or placebo daily, along with supportive care with renin-angiotensin system inhibition. This was followed by a 15-month off-drug observational period allowing for continued supportive care.
  • For the subanalysis, the patients were further stratified on the basis of eGFR deciles in relation to the overall study population, with levels above and below 38, 43, 47, 51, 55, 60, 66, 72, and 82 mL/min/1.73 m2.
  • The median eGFR overall was 55.49 mL/min/1.73 m2 and was balanced across the Nefecon and placebo groups.

TAKEAWAY: 

  • The relative benefit of Nefecon in terms of eGFR was seen across most deciles and timepoints and showed a generally greater benefit in higher baseline eGFR groups (above 72 mL/min/1.73 m2).
  • Furthermore, the relative urine protein-creatinine ratio benefit was observed from month 9 with Nefecon vs placebo regardless of baseline eGFR, with a continued reduction to month 12, followed by a maintained treatment benefit to month 24.
  • The eGFR benefits with Nefecon over placebo were observed among patients within the upper and lower deciles over 2 years.
  • eGFR showed a pronounced on-treatment benefit and a delay in decline during the observation period.

IN PRACTICE:

“This NefIgArd subanalysis demonstrated that the efficacy of a 9-month Nefecon treatment course in reduction of proteinuria and preservation of kidney function was independent of baseline eGFR,” said first author Jonathan Barratt, MD, of the College of Life Sciences, University of Leicester, UK.

“So, we should be confident about treating people with Nefecon across the full range of eGFR in terms of the eGFR saving we’re going to see, but also the proteinuria reduction,” he added.

SOURCE:

The findings were reported this week at the 62nd European Renal Association (ERA) Congress 2025.

DISCLOSURES:

The study was funded by Calliditas Therapeutics AB.



Source link : https://www.medscape.com/viewarticle/nefecon-shows-igan-benefits-regardless-baseline-egfr-2025a1000fcd?src=rss

Author :

Publish date : 2025-06-06 18:08:00

Copyright for syndicated content belongs to the linked Source.

Previous Post

Why Choose Second Opinions? Risky Cancer Searches; 18 Months to Live, 20 Years Later

Next Post

Sibeprenlimab Halves uPCR in IgA Nephropathy Trial

Related Posts

Health News

Proton Pump Inhibitors and Hypertension; AI Fetal Cardiac Scans; ‘Work Diet’

July 1, 2025
Health News

Fixable Factors Help Drive Disparities in Access to COVID Treatment

July 1, 2025
Health News

A Neanderthal-shaped skull may explain why some people get headaches

July 1, 2025
Health News

Synthetic Nicotine Storms Onto the Vaping Scene

July 1, 2025
Health News

How to Have ‘The Talk’ — About Vaccines

July 1, 2025
Health News

‘Notable’ rise in dads over 60 in England and Wales

July 1, 2025
Load More

Proton Pump Inhibitors and Hypertension; AI Fetal Cardiac Scans; ‘Work Diet’

July 1, 2025

Fixable Factors Help Drive Disparities in Access to COVID Treatment

July 1, 2025

A Neanderthal-shaped skull may explain why some people get headaches

July 1, 2025

Synthetic Nicotine Storms Onto the Vaping Scene

July 1, 2025

How to Have ‘The Talk’ — About Vaccines

July 1, 2025

‘Notable’ rise in dads over 60 in England and Wales

July 1, 2025

Earwax Secretions May Help Detect Parkinson’s Disease

July 1, 2025

Gastric Procedure Alleviates GERD Symptoms in Obesity

July 1, 2025
Load More

Categories

Archives

July 2025
MTWTFSS
 123456
78910111213
14151617181920
21222324252627
28293031 
« Jun    

© 2022 NewsHealth.

No Result
View All Result
  • Health News
  • Hair Products
  • Nutrition
    • Weight Loss
  • Sexual Health
  • Skin Care
  • Women’s Health
    • Men’s Health

© 2022 NewsHealth.

Go to mobile version